Hematologia

Estudo randomizado | Entre pacientes internados com COVID-19 sob risco de tromboembolismo venoso, a tromboprofilaxia pós-alta hospitalar com rivaroxabam por 35 dias pode melhorar os desfechos.

17 Dez, 2021 | 12:26h

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Comentário convidado: Anticoagulation in COVID-19 – The Lancet

 

Comentário no Twitter

NEW: The role of extended thromboprophylaxis in patients hospitalised with COVID-19 at risk for thrombotic events after discharge – findings from MICHELLE trial https://t.co/OWcmjCLBTw pic.twitter.com/3Bl4lV16Va

— The Lancet (@TheLancet) December 16, 2021

 

---

COVID-19 e trombose: busca por evidências.

13 Dez, 2021 | 11:35h

COVID-19 and thrombosis: searching for evidence – Hematology, ASH Education Program

---

Como reconhecer e tratar a coagulopatia associada a COVID-19.

13 Dez, 2021 | 11:34h

How to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program

---

Programa educacional da ASH | Hematology – Séries de artigos de revisão com casos clínicos publicados anualmente pela American Society of Hematology.

13 Dez, 2021 | 11:23h

Página principal: Hematology, the ASH Education Program

---

Estudo randomizado de não inferioridade mostrou que a radioterapia pode ser seguramente omitida em muitas crianças e adolescentes em estágios intermediário e avançado de linfoma de Hodgkin clássico.

10 Dez, 2021 | 11:06h

Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial – The Lancet Oncology

 

---

Atualização no diagnóstico e no tratamento da embolia pulmonar aguda para médicos de outras áreas que não a respiratória.

9 Dez, 2021 | 15:17h

Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician – Clinical Medicine Journal

---

OMS faz recomendação contra o uso de plasma convalescente para tratar COVID-19.

8 Dez, 2021 | 13:22h

Comunicado de imprensa: WHO recommends against the use of convalescent plasma to treat COVID-19 – World Health Organization

Ver orientação: WHO’s living guidelines on COVID-19 therapeutics

Infográfico: A living WHO guideline on drugs for covid-19 – The BMJ

 

Comentário no Twitter (fio – clique para saber mais)

Convalescent plasma is a transfusion of blood plasma from someone who has recovered from #COVID19, and is used as a treatment for COVID19 https://t.co/Bobq7OTDGq pic.twitter.com/pfO1sFvUpJ

— World Health Organization (WHO) (@WHO) December 7, 2021

 

---

Posicionamento ESC | Seguimento ótimo após embolia pulmonar aguda.

8 Dez, 2021 | 13:09h

Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society – European Heart Journal

 

Comentário no Twitter

Do you routinely discuss how/when to resume sporting activities and traveling with your PE patients? Or future cardiovascular risk? Check this recent ESC/ERS position paper on optimal follow-up of acute PE for these and other key aspects of counselling: https://t.co/KEQ7FnFwXX

— Erik Klok (@Erik_Klok_MD) December 7, 2021

 

---

Estudo randomizado | Maribavir para infecções por citomegalovírus refratárias com ou sem resistência pós-transplante.

7 Dez, 2021 | 11:29h

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial – Clinical Infectious Diseases

---

Outro estudo randomizado mostrou que o plasma convalescente não beneficia pacientes internados com Covid-19.

1 Dez, 2021 | 15:36h

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

Conteúdos relacionados:

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Comentário no Twitter

The TSUNAMI RCT showed that high-titer convalescent plasma (CP) did not reduce the risk of severe respiratory failure or death in hospitalized patients with #COVID19 pneumonia. https://t.co/4q0S2AtfMj

— JAMA Network Open (@JAMANetworkOpen) November 29, 2021

 

---